###begin article-title 0
###xml 70 73 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 225 229 225 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vpr </italic>
###xml 51 56 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 66 73 <span type="species:ncbi:9606">patient</span>
###xml 209 216 <span type="species:ncbi:9606">patient</span>
###xml 577 580 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We previously reported an epidemiologically linked HIV-1 infected patient cohort in which a long-term non-progressor (LTNP) infected two recipients who then exhibited normal disease progression. Expression of patient-derived vpr sequences from each of the three cohort members in mammalian cells tagged with GFP revealed a significant reduction in Vpr nuclear import and virion incorporation uniquely from the LTNP, whereas Vpr from the two progressing recipients displayed normal localisation and virion incorporation, implying a link between efficient Vpr nuclear import and HIV disease progression. Importantly, an F72L point mutation in the LTNP was identified for the first time as being uniquely responsible for decreased Vpr nuclear import.
###end p 2
###begin title 3
Findings
###end title 3
###begin p 4
###xml 108 115 108 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 399 401 399 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 528 529 528 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 865 867 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 21 24 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 78 81 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 320 323 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 581 584 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 894 897 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The highly conserved HIV accessory protein Viral Protein R (Vpr) is vital for HIV infection and replication in vivo, particularly within non-dividing cells, including terminally differentiated T-cells and macrophages where nuclear envelope integrity is permanently maintained [1-5]. On its own and within the context of HIV infection [6,7], Vpr has been shown to localize to the nucleus and induce G2 cell-cycle arrest through hyperphosphorylation of p34-cdc2, which provides the most optimal environment for viral replication [8-13], followed closely by apoptosis [14-21]. During HIV infection, Vpr associates with the viral cDNA containing Pre-integration Complex (PIC) increasing its affinity for components of the cellular nuclear import machinery [22-25] through the activity of 2 distinct nuclear localization signals (NLSs) within its N- [26] and C-termini [27], thus driving productive HIV infection.
###end p 4
###begin p 5
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 246 250 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vpr </italic>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 77 80 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 273 276 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We previously reported [28] on a cohort spanning 1992 to 2000, comprising an HIV+ long-term non-progressor (LTNP) (donor A) and two recipients (B and C) who upon transmission (autumn and summer 1989 respectively) from donor A progressed to AIDS. Vpr sequences derived from HIV pro-viral DNA isolated from PBMCs as well as circulating virus, revealed that sequences from the progressing recipients differed markedly to those of the LTNP founder virus host, providing the first evidence for Vpr positive selection during disease progression in an epidemiologically-linked cohort (see also [29]).
###end p 5
###begin p 6
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vpr </italic>
###xml 631 640 622 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">not shown</italic>
###xml 817 821 808 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vpr </italic>
###xml 968 969 959 960 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 982 983 973 974 <bold xmlns:xlink="http://www.w3.org/1999/xlink">6</bold>
###xml 991 993 982 984 <bold xmlns:xlink="http://www.w3.org/1999/xlink">#2</bold>
###xml 1001 1003 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1043 1045 1034 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1064 1069 1055 1060 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 1075 1077 1066 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1162 1164 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1254 1256 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1469 1474 1460 1465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 1497 1502 1488 1493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">A6-2 </sup>
###xml 1624 1629 1615 1620 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 1640 1645 1631 1636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">B6-4 </sup>
###xml 1655 1661 1646 1652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">C11-1 </sup>
###xml 1667 1669 1658 1660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 158 163 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 960 967 <span type="species:ncbi:9606">patient</span>
###xml 1125 1133 <span type="species:ncbi:9606">patients</span>
In this study, cohort-derived GFP-Vpr mammalian cell expression vectors were used to investigate Vpr subcellular localisation and nuclear import. In total, 4 HIV-1 vpr clones were isolated from donor A (A1, A3, A5 and A6 corresponding to years 1996, 1998, 1999 and 2000), 4 from recipient B (B3, B4, B5 and B6 corresponding to years 1997, 1998, 1998 and 1999) and 7 from recipient C (C2, C3, C5, C6, C8, C10 and C11 from 1992, 1992, 1993, 1994, 1994, 1998 and 1999 respectively) and used to generate the GFP-Vpr expression constructs. Lipofectaminetrade mark 2000 (Invitrogen) was used to transfect constructs into HeLa and COS-7 (not shown) cells, followed by imaging 14 hours post transfection using an Olympus FV-1000 confocal laser scanning microscope (CLSM), with similar results. Initial analysis of late-stage vpr gene products from all 3 donors revealed a reduction in nuclear fluorescence accompanied by perinuclear accumulation for LTNP sample A6-2 (patient A, time-point 6, clone #2) (Fig. 1A(iii)) compared to pUC18-NL4.3 derived [30] wild-type GFP-Vpr1-96 (Fig. 1A(ii)): a phenotype not observed in samples from patients B (B6-4) nor C (C11-1) (Fig 1A(iv, v)). Quantification of nuclear import was determined using ImageJ analysis software [31] where the ratio of nuclear (Fn) to cytoplasmic (Fc) fluorescence, subtracting background (B) was calculated, Fn/c = (Fn-B)/(Fc-B). A highly significant (p < 0.0001) reduction in Fn/c was observed between GFP-Vpr1-96 (Fn/c ~2.4) and GFP-VprA6-2 (Fn/c ~0.9) indicating a reduction in nuclear accumulation. No significant difference in Fn/c was observed between GFP-Vpr1-96 and GFP-VprB6-4 or GFP-VprC11-1 (Fig. 1B).
###end p 6
###begin p 7
###xml 0 141 0 141 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Late-stage LTNP-derived GFP-Vpr samples show decreased levels of nuclear accumulation compared to wildtype Vpr and progressing donors B and C</bold>
###xml 143 147 143 147 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 319 323 310 314 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 355 356 346 347 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 587 591 578 582 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
###xml 628 632 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vpr </italic>
###xml 443 450 <span type="species:ncbi:9606">patient</span>
###xml 612 619 <span type="species:ncbi:9606">patient</span>
Late-stage LTNP-derived GFP-Vpr samples show decreased levels of nuclear accumulation compared to wildtype Vpr and progressing donors B and C. (A) HeLa cells were transfected with indicated GFP-Vpr constructs using Lipofectamine 2000trade mark with confocal images obtained 14 hours later using an Olympus FV1000 CLSM. (B) Analysis of CLSM images (as per A) with ImageJ was performed to determine the Fn/c. As a whole, late-stage samples from patient A (A6-2, A6-3, A6-4) and the Vpr (F72L) point mutant displayed significantly (p < 0.0001) reduced Fn/c ratios compared to wildtype Vpr. (C) Sequence analysis of patient-derived vpr sequences identifies F72L substitution mutation (as indicated) uniquely within all GFP-Vpr constructs with reduced nuclear accumulation.
###end p 7
###begin p 8
###xml 217 221 217 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">A1-2</sup>
###xml 240 244 240 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">A3-1</sup>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 341 346 341 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
To establish if decreased Vpr nuclear accumulation was a specifically conserved viral feature of the LTNP or an acquired trait, GFP-Vpr constructs from early-cohort timepoints were analysed. Samples from 1996 (GFP-VprA1-2) and 1998 (GFP-VprA3-1) (Fig. 1A(vi, vii)) both displayed levels of nuclear accumulation comparable to wildtype GFP-Vpr1-96 (Fig. 1B), implying that loss of nuclear import occurred post 1998.
###end p 8
###begin p 9
###xml 140 199 140 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">clone A6-5 data not shown as sequence is homologous to A6-3</italic>
###xml 279 284 279 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 342 346 342 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">A6-4</sup>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 566 571 566 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">A6-2 </sup>
###xml 578 584 578 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">A6-3/5</sup>
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 729 733 729 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink">A6-4</sup>
###xml 801 807 801 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink">A6-3/5</sup>
###xml 967 969 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
With the loss of efficient nuclear accumulation identified as a late-stage LTNP trait, further analysis of late-stage clones A6-3 and A6-5 (clone A6-5 data not shown as sequence is homologous to A6-3) was performed, revealing Fn/c values significantly lower than wildtype GFP-Vpr1-96 (Fig. 1B). Of interest, a single late-stage clone (GFP-VprA6-4) displayed a small degree of nuclear accumulation (Fig. 1A(ix)), although at levels significantly reduced compared to wildtype (Fig. 1B). Sequence analysis revealed that all clones with reduced nuclear accumulation (VprA6-2 and VprA6-3/5) contained a phenylalanine to leucine mutation at amino acid position 72 (F72L) (Fig. 1C). This mutation is absent in the nuclear localizing VprA6-4, which is otherwise identical in sequence to late-stage samples VprA6-3/5. Analysis of our database containing over 1200 published and unpublished Vpr sequences revealed that the F72L mutation has only been reported once previously [32].
###end p 9
###begin p 10
###xml 166 170 166 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">F72L</sup>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 250 255 250 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">F72L </sup>
###xml 311 316 311 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 381 386 381 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">A6-2 </sup>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1076 1077 1072 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1321 1322 1317 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
To determine the specific role of F72L in abrogation of Vpr nuclear import, an F72L substitution was engineered into wildtype Vpr and an expression construct (GFP-VprF72L) produced. Subsequent transfection (Fig. 1A(x)) revealed a reduction in GFP-VprF72L nuclear accumulation when compared with wildtype GFP-Vpr1-96 (Fig. 1A(ii)), in a similar fashion to clinically derived GFP-VprA6-2 (Fig. 1B), thus confirming F72L as a probable mechanism for the observed reduction in nuclear accumulation within late-stage LTNP samples. This reduction in nuclear import was accompanied by an accumulation of GFP-Vpr protein within the perinuclear region of the cell, concordant with an area encompassing the proposed location of the Golgi. Colocalisation studies with the Golgi-specific marker protein gamma-adaptin revealed that Vpr proteins harbouring the F72L point mutation, but not those with wildtype phenylalanine, were localized to the Golgi apparatus, implying that reduced nuclear accumulation could in part be attributed to this mislocalisation of GFP-Vpr (see Additional file 1). The lack of colocalisation between F72L-containing Vpr proteins and the endoplasmic reticulum (ER) marker Calnexin (Sigma, C-4731), confirmed that Vpr mislocalisation to the Golgi is not a result of general mistargeting (see Additional file 2).
###end p 10
###begin p 11
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 307 312 307 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">F72L </sup>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 940 942 936 938 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 948 949 944 945 <underline xmlns:xlink="http://www.w3.org/1999/xlink">M</underline>
###xml 961 962 957 958 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A</underline>
###xml 977 978 973 974 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 991 992 987 988 <underline xmlns:xlink="http://www.w3.org/1999/xlink">I</underline>
###xml 1326 1328 1315 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1592 1597 1578 1583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 1603 1605 1589 1591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1731 1733 1717 1719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1865 1866 1851 1852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1867 1869 1853 1855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1870 1872 1856 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1873 1875 1859 1861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 877 880 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1036 1041 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1822 1825 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Although the precise pathways involved are still debated, efficient nuclear export [33] and/or cytoplasmic retention [34] of Vpr during viral infection has been identified as a key requirement for virion incorporation. With this in mind, we assessed the ability of nuclear import-inhibited cytosolic GFP-VprF72L to incorporate into forming virions. Briefly, 293T cells were cotransfected with a panel of GFP-Vpr expression vectors as well as the proviral plasmid pUC18-NL4.3, with the resultant virions analysed by Western blotting for GFP-Vpr incorporation. Interestingly we found that all F72L-containing GFP-Vpr proteins that failed to significantly localize within the nucleus, were absent from purified viral lysates (Fig. 2A), implying a possible link between the efficient nuclear transport of Vpr and virion incorporation. To examine the effect of the F72L mutation on HIV infectivity, we infected gamma-irradiated, non-dividing CD4+ MAGI (Multinuclear Activation of a Galactosidase Indicator) cells which contain an integrated HIV-1-LTR-beta-galactosidase gene with virus derived from 293T cells cotransfected with DeltaVpr pro-virus and wildtype or F72L-containing GFP-Vpr encoding plasmids. 48 hours post infection, MAGI cells were fixed and stained with 5-bromo-4-chloro-3-indolyl-beta-Dgalactopyranoside (X-gal) [35], followed by scoring for infected cells (blue nuclei) due to LTR-beta-gal transactivation by viral Tat protein. Virus derived from all F72L-containing plasmids showed a significant (p < 0.0001), 5-fold reduction in viral infectivity when compared to wildtype Vpr1-96 (Fig. 2B). This dramatic reduction in infectivity presumably stems from the lack of virion incorporation of F72L-containing Vpr (Fig. 2A) and resultant absence of Vpr-facilitated PIC nuclear import, a key factor in efficient HIV replication within non-dividing cells [1,24,25,36].
###end p 11
###begin p 12
###xml 0 237 0 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F72L-containing GFP-Vpr proteins fail to incorporate into forming virions, which show decreased infectivity of non-dividing MAGI (Multinuclear Activation of a Galactosidase Indicator) cells correlating with reduced importin-&#946;3 binding</bold>
###xml 239 241 236 238 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A</bold>
###xml 579 583 576 580 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 848 849 837 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1049 1050 1035 1036 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1580 1584 1554 1558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96</sup>
###xml 1756 1760 1730 1734 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96</sup>
###xml 1762 1766 1736 1740 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
###xml 1817 1822 1790 1795 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 1924 1928 1879 1883 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(D) </bold>
###xml 1993 1998 1947 1952 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 2008 2013 1962 1967 <sup xmlns:xlink="http://www.w3.org/1999/xlink">F72L </sup>
###xml 2178 2180 2129 2131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 2258 2259 2209 2210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 2259 2260 2210 2211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 2263 2268 2214 2219 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(E)i </bold>
###xml 2568 2574 2516 2522 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(E)ii </bold>
###xml 2606 2610 2554 2558 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E(i)</bold>
###xml 2779 2783 2724 2728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96</sup>
###xml 2808 2813 2753 2758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">F72L </sup>
###xml 2839 2843 2784 2788 <sup xmlns:xlink="http://www.w3.org/1999/xlink">A6-3</sup>
###xml 862 867 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1239 1242 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1272 1275 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2394 2399 <span type="species:ncbi:9606">human</span>
F72L-containing GFP-Vpr proteins fail to incorporate into forming virions, which show decreased infectivity of non-dividing MAGI (Multinuclear Activation of a Galactosidase Indicator) cells correlating with reduced importin-beta3 binding. (A) Virus was derived from 293T cells cotransfected with pEPI-GFP-Vpr and proviral plasmid pUC18-NL4.3 and subjected to Western blot analysis, revealing the absence of GFP-Vpr protein in F72L containing samples. Control staining for p24 capsid protein indicates the presence of virus in all samples (*denotes lack of virion incorporation). (B) Virus derived from 293T cells cotransfected with the DeltaVpr pro-viral plasmid pUC18-NL4.3(FS) and pEPI-GFP-Vpr (1-96, A6-2, A6-3 or F72L) was purified, normalized using an RT assay and used to infect growth arrested (gamma-irradiated, 2 cycles at 30 Gy) MAGI (CD4+, integrated HIV-1-LTR-beta-gal) cells. 48 hours post infection cells were fixed (1% formaldehyde/0.2% glutaraldehyde/PBS), stained (4 mM potassium ferricyanide, 4 mM potassium ferrocyanide, 2 mM MgCl2, 0.4 mg/ml 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside [X-gal]) and scored for viral infectivity. Infected cells display X-gal stained (blue) nuclei due to expression of the early HIV protein Tat, which binds the HIV-LTR promoter of the integrated beta-gal gene, resulting in expression of the beta-gal protein. Non-infected cells remain colourless due to the lack of Tat expression and subsequent activation of the beta-gal gene. Data presented depicts relative levels of infectivity (% +/- SEM) compared to wildtype Vpr1-96. Virus derived from F72L-cotransfected 293T cells displayed a significant (p < 0.0001) 5-fold reduction in viral infectivity of non-dividing cells compared to wildtype Vpr1-96. (C) Native PAGE gel-shift mobility assay; 2 muM GFP-Vpr1-96 or GFP alone was incubated with 10 muM importin-alpha2, -beta1, -alpha2/beta1 or -beta3 as indicated. (D) Native PAGE gel-shift mobility titration assay; (i) 2 muM GFP-Vpr1-96 or GFP-VprF72L was incubated with increasing concentrations of Importin-beta3 protein as indicated. (ii) Fluorimetric analysis of gel-shift assays from D(i), was performed as per [39] with the binding curves generated used to calculate dissociation constants (Kd). (E)i Typical CLSM images of fixed COS-7 cells expressing the indicated GFP-fusion proteins alone or in the context of c-myc-tagged-human Importin-beta3. Cells were permeabilised and stained 14 hours post transfection with anti-c-myc antibody (Sigma) and visualized with Alexa-Fluo-568 (Molecular Probes). (E)ii Analysis of CLSM images (as per E(i)) with ImageJ was performed to determine the Fn/c. Exogenous Importin-beta3 was found to significantly (p = 0.0378) increase the nuclear accumulation of wildtype GFP-Vpr1-96, but not that of GFP-VprF72L or F72L containing GFP-VprA6-3.
###end p 12
###begin p 13
###xml 99 101 95 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">20</sup>
###xml 108 110 104 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">26</sup>
###xml 159 161 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 162 164 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 209 219 205 215 <underline xmlns:xlink="http://www.w3.org/1999/xlink">underlined</underline>
###xml 222 224 218 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">71</sup>
###xml 225 226 221 222 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 226 228 222 224 <underline xmlns:xlink="http://www.w3.org/1999/xlink">RI</underline>
###xml 229 230 225 226 <underline xmlns:xlink="http://www.w3.org/1999/xlink">C</underline>
###xml 238 242 234 238 <underline xmlns:xlink="http://www.w3.org/1999/xlink">RQRR</underline>
###xml 243 244 239 240 <underline xmlns:xlink="http://www.w3.org/1999/xlink">R</underline>
###xml 244 246 240 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">90</sup>
###xml 253 255 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 472 474 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 527 532 523 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 543 548 539 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">F72L </sup>
###xml 628 633 624 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 843 845 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 880 885 856 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">F72L </sup>
###xml 945 950 918 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96 </sup>
###xml 952 954 925 927 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d </sub>
###xml 985 987 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 1090 1098 1058 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo </italic>
###xml 1205 1209 1170 1174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;96</sup>
###xml 1234 1239 1199 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">F72L </sup>
###xml 1249 1253 1214 1218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">A6-3</sup>
###xml 1425 1427 1384 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2E</xref>
###xml 672 677 <span type="species:ncbi:9606">human</span>
Nuclear accumulation of Vpr is governed by 2 distinct NLSs; a leucine-rich N-terminal alpha-helix (20LELLEEL26) which has been linked to virion incorporation [37,38], and a C-terminal arginine-rich bipartite (underlined) (71HFRIGCRHSRIGVTRQRRAR90) NLS [27] which incorporates phenylalanine 72 (bold). To determine if the identified F72L substitution affects the function of Vpr's C-terminal NLS, we used a previously described fluorescence based gel-shift mobility assay [39] to compare the interaction between wildtype GFP-Vpr1-96 and GFP-VprF72L with a panel of purified importin proteins. We established that wildtype GFP-Vpr1-96 was able to bind with high affinity to human Importin-beta3 (hbeta3) but not other members of the importin superfamily, including Importin-beta1, Importin-alpha2 or the Importin-alpha2/beta1 heterodimer. (Fig. 2C). Titrations revealed that GFP-VprF72L was unable to bind hbeta3 as effectively as wildtype GFP-Vpr1-96 (Kd = 0.66 muM vs. 1.60 muM) (Fig. 2D(i, ii)), indicating a direct relationship between F72L and decreased Importin-beta3 binding capacity. In vivo cotransfection of GFP-Vpr constructs with Importin-beta3 was found to increase the Fn/c of wildtype GFP-Vpr1-96, but not that of GFP-VprF72L or GFP-VprA6-3, consistent with the idea that Importin-beta3 contributes to nuclear import of Vpr, and that the F72L mutation impacts on recognition by Importin-beta3 directly (see Fig. 2E(i, ii)). We therefore propose that the F72L mutation itself leads to decreased Vpr nuclear import and consequently reduced virion incorporation due to reduced binding efficiency to Importin-beta3.
###end p 13
###begin p 14
###xml 48 56 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vpr </italic>
###xml 184 192 184 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 644 646 644 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 934 936 933 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1119 1120 1118 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1121 1123 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1124 1126 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1127 1129 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1381 1383 1380 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1908 1910 1907 1909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1911 1913 1910 1912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1914 1916 1913 1915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 719 722 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 991 994 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1199 1206 <span type="species:ncbi:9606">patient</span>
###xml 1358 1361 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
It does not seem unreasonable to speculate that in vivo selective pressures have driven the evolution of functionally-attenuated vpr to ensure long-term viral survival and replication in vivo [2,5,40-42]. Our study shows that F72L-containing Vpr does not accumulate within host cell nuclei or incorporate into nascent virions; subsequent infections with such a Vpr-deficient virus are less efficient, leading to reduced virus production [41-43] and ultimately a lack of deterioration in T-cell numbers, as in the case of the LTNP. Many of our observations are concordant with analysis of LTNP infection status in 2000, which revealed normal CD4+ T-cell levels (>550 cells per mul) suggesting the absence of significant HIV-mediated T-cell targeting and depletion. Since our data here suggests that c. 75% of late-stage proviral strains in the LTNP would produce virions lacking Vpr due to the F72L mutation, the levels of observed CD4+ T-cells within the LTNP may be due to the inability of HIV lacking Vpr to import the viral genome into the non-dividing host cell nucleus and carry out subsequent steps of infection [1,24,25,44]. Presumably one advantage for the virus is that the preservation of patient health status leads to enhanced probability of transmission to new hosts, thus leading to increased virus spread. Low levels of virus production (<425 HIV copies/ml plasma) [29] are presumably maintained through the activity of a small subset of Vpr quasi-species that do not contain the F72L mutation (A6-4) or perhaps viruses that we were unable to characterize due to their low prevalence. Additional to all of the above considerations, it is important to remember that the effects of decreased Vpr nuclear import through the F72L mutation are likely to be influenced by many other factors, including host genetic make-up and immune response, which in themselves can influence disease progression [28,45-49].
###end p 14
###begin p 15
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 459 464 459 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink">F72L </sup>
###xml 587 592 587 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">F72L </sup>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 802 806 802 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vpr </italic>
###xml 170 173 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 469 472 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In summary this study provides evidence for a naturally occurring Vpr mutation within an epidemiologically-linked cohort and its possible contribution to non-progressive HIV disease status through disruption of efficient nuclear transport and apparent lack of viral incorporation, leading to reduced infectivity of non-dividing cells (Fig. 2B). To demonstrate formally the link between Vpr nuclear localisation and disease progression, further analysis of VprF72L in a HIV infectious system is required, eg. to dismiss the possibility that the effects in terms of lack of assembly of VprF72L may in part be due to impaired p6gag binding, stemming from conformational or other effects. With this proviso in mind, however, the work here and elsewhere (see also [50]) implies that functional selection of vpr viral quasispecies in concert with host selection pressure over time, as evident in the LTNP, may be a factor in determining the rate of disease progression.
###end p 15
###begin title 16
Supplementary Material
###end title 16
###begin title 17
Additional file 1
###end title 17
###begin p 18
###xml 0 85 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LTNP derived Vpr proteins with reduced nuclear accumulation localize within the Golgi</bold>
LTNP derived Vpr proteins with reduced nuclear accumulation localize within the Golgi. Typical CLSM images of fixed COS-7 cells expressing the indicated GFP-fusion proteins. Cells were permeabilised and stained 14 hours post transfection for gamma-adaptin and visualized with Alexa-Fluor-568. GFP-Vpr proteins specifically containing F72L show colocalisation with the Golgi apparatus as indicated by arrows.
###end p 18
###begin p 19
Click here for file
###end p 19
###begin title 20
Additional file 2
###end title 20
###begin p 21
###xml 0 85 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LTNP derived Vpr proteins with reduced nuclear accumulation localize within the Golgi</bold>
LTNP derived Vpr proteins with reduced nuclear accumulation localize within the Golgi. Typical CLSM images of fixed COS-7 cells expressing the indicated GFP-fusion proteins. Cells were permeabilised and stained 14 hours post transfection for Calnexin and visualized with Alexa-Fluor-568. GFP-Vpr was found to not localize within the ER.
###end p 21
###begin p 22
Click here for file
###end p 22
###begin title 23
Acknowledgements
###end title 23
###begin p 24
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
Bin Wang and Meriet Mikhail (Millennium Institute), and Michael Gill and Brenda Beckthold (University of Calgary) are acknowledged for providing the samples from the cohort patients that were used for our published study [28], on which the present work builds. Part of the work was funded by NHMRC project grant #222744 to SCP and DAJ, and NHMRC Senior fellowship #384109 to DAJ.
###end p 24
###begin article-title 25
###xml 19 54 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in non-dividing host cells
###end article-title 25
###begin article-title 26
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Nuclear localization of Vpr is crucial for the efficient replication of HIV-1 in primary CD4+ T cells
###end article-title 26
###begin article-title 27
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The Vpr protein from HIV-1: distinct roles along the viral life cycle
###end article-title 27
###begin article-title 28
###xml 56 91 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1
###end article-title 28
###begin article-title 29
###xml 40 75 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 117 122 <span type="species:ncbi:9606">human</span>
Vpr and Vpu are important for efficient human immunodeficiency virus type 1 replication and CD4+ T-cell depletion in human lymphoid tissue ex vivo
###end article-title 29
###begin article-title 30
###xml 20 25 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways
###end article-title 30
###begin article-title 31
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Arginine residues in the C-terminus of HIV-1 Vpr are important for nuclear localization and cell cycle arrest
###end article-title 31
###begin article-title 32
###xml 10 15 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of HIV-1 Vpr on cell cycle regulators
###end article-title 32
###begin article-title 33
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 42 55 <span type="species:ncbi:4896">fission yeast</span>
###xml 57 82 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
HIV-1 Vpr induces cell cycle G2 arrest in fission yeast (Schizosaccharomyces pombe) through a pathway involving regulatory and catalytic subunits of PP2A and acting on both Wee1 and Cdc25
###end article-title 33
###begin article-title 34
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 42 55 <span type="species:ncbi:4896">fission yeast</span>
HIV-1 Vpr induces G2 cell cycle arrest in fission yeast associated with Rad24/14-3-3-dependent, Chk1/Cds1-independent Wee1 upregulation
###end article-title 34
###begin article-title 35
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vpr-dependent cell cycle arrest through a mitogen-activated protein kinase signal transduction pathway
###end article-title 35
###begin article-title 36
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation
###end article-title 36
###begin article-title 37
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo
###end article-title 37
###begin article-title 38
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vpr-induced Apoptosis Is Cell Cycle Dependent and Requires Bax but Not ANT
###end article-title 38
###begin article-title 39
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
ATR and GADD45alpha mediate HIV-1 Vpr-induced apoptosis
###end article-title 39
###begin article-title 40
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 122 127 <span type="species:ncbi:9606">human</span>
A C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human CD4+ lymphocytes
###end article-title 40
###begin article-title 41
Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of alphavbeta3-expressing endothelial cells
###end article-title 41
###begin article-title 42
Viral proteins targeting mitochondria: controlling cell death
###end article-title 42
###begin article-title 43
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Analysis of apoptosis induced by HIV-1 Vpr and examination of the possible role of the hHR23A protein
###end article-title 43
###begin article-title 44
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 61 66 <span type="species:ncbi:9606">Human</span>
Human Immunodeficiency Virus Type 1 Vpr Induces Apoptosis in Human Neuronal Cells
###end article-title 44
###begin article-title 45
Studies with GFP-Vpr fusion proteins: induction of apoptosis but ablation of cell-cycle arrest despite nuclear membrane or nuclear localization
###end article-title 45
###begin article-title 46
###xml 47 50 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Visualization of the intracellular behavior of HIV in living cells
###end article-title 46
###begin article-title 47
###xml 74 77 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Nuclear import of the pre-integration complex (PIC): the Achilles heel of HIV?
###end article-title 47
###begin article-title 48
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex
###end article-title 48
###begin article-title 49
###xml 48 53 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Viral protein R regulates nuclear import of the HIV-1 pre-integration complex
###end article-title 49
###begin article-title 50
###xml 38 73 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Two putative alpha-helical domains of human immunodeficiency virus type 1 Vpr mediate nuclear localization by at least two mechanisms
###end article-title 50
###begin article-title 51
###xml 31 66 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr
###end article-title 51
###begin article-title 52
###xml 42 45 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 77 80 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Evidence for host-driven selection of the HIV type 1 vpr gene in vivo during HIV disease progression in a transfusion-acquired cohort
###end article-title 52
###begin article-title 53
###xml 12 15 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 60 63 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Full-length HIV type 1 genome analysis showing evidence for HIV type 1 transmission from a nonprogressor to two recipients who progressed to AIDS
###end article-title 53
###begin article-title 54
###xml 74 79 <span type="species:ncbi:9606">human</span>
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone
###end article-title 54
###begin article-title 55
Image Processing with ImageJ
###end article-title 55
###begin article-title 56
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
High prevalence of diverse forms of HIV-1 intersubtype recombinants in Central Myanmar: geographical hot spot of extensive recombination
###end article-title 56
###begin article-title 57
###xml 63 98 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages
###end article-title 57
###begin article-title 58
###xml 18 53 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging
###end article-title 58
###begin article-title 59
###xml 51 79 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene
###end article-title 59
###begin article-title 60
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection
###end article-title 60
###begin article-title 61
###xml 123 158 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr
###end article-title 61
###begin article-title 62
###xml 22 57 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation
###end article-title 62
###begin article-title 63
Quantitative analysis of protein-protein interactions by native page/fluorimaging
###end article-title 63
###begin article-title 64
###xml 48 53 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Evidence for a cytopathogenicity determinant in HIV-1 Vpr
###end article-title 64
###begin article-title 65
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
###xml 114 119 <span type="species:ncbi:9606">human</span>
Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages
###end article-title 65
###begin article-title 66
###xml 60 95 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells
###end article-title 66
###begin article-title 67
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vpr transactivates LTR-directed expression through sequences present within -278 to -176 and increases virus replication in vitro
###end article-title 67
###begin article-title 68
###xml 11 46 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
A role for human immunodeficiency virus type 1 Vpr during infection of peripheral blood mononuclear cells
###end article-title 68
###begin article-title 69
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Vpr is preferentially targeted by CTL during HIV-1 infection
###end article-title 69
###begin article-title 70
Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay
###end article-title 70
###begin article-title 71
Intrinsic immunity: a front-line defense against viral attack
###end article-title 71
###begin article-title 72
###xml 35 40 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection
###end article-title 72
###begin article-title 73
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 viral protein R (Vpr) & host cellular responses
###end article-title 73
###begin article-title 74
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Molecular characterization of the HIV type 1 vpr gene in infected Chinese former blood/plasma donors at different stages of diseases
###end article-title 74

